HIF2α Activation in NASH: A New Force Pushing Toward HCC.
作者信息
Clavería-Cabello Alex, Avila Matías A
机构信息
Hepatology Program, CIMA, University of Navarra, Pamplona, Spain; Maite G. Fernandez-Barrena, Hepatology Program, CIMA, University of Navarra, Pamplona, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain.
Hepatology Program, CIMA, University of Navarra, Pamplona, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain.
出版信息
Cell Mol Gastroenterol Hepatol. 2022;13(2):678-680. doi: 10.1016/j.jcmgh.2021.11.005. Epub 2021 Nov 27.
Abstract
摘要
相似文献
1
HIF2α Activation in NASH: A New Force Pushing Toward HCC.非酒精性脂肪性肝炎中低氧诱导因子2α的激活：推动肝细胞癌发生的新力量。
Cell Mol Gastroenterol Hepatol. 2022;13(2):678-680. doi: 10.1016/j.jcmgh.2021.11.005. Epub 2021 Nov 27.
2
Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.巨噬细胞凋亡抑制剂的激活是 NASH 相关肝细胞癌的敏感诊断标志物。
J Gastroenterol. 2018 Jun;53(6):770-779. doi: 10.1007/s00535-017-1398-y. Epub 2017 Oct 30.
3
Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.非酒精性脂肪性肝炎与酒精相关肝细胞癌的比较。
Clin Mol Hepatol. 2020 Apr;26(2):196-208. doi: 10.3350/cmh.2019.0012. Epub 2020 Jan 9.
4
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.非酒精性脂肪性肝病相关肝细胞癌：日益受到关注。
Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17.
5
[Which animal models of nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC) have more practical value in experimental investigations?].[哪种非酒精性脂肪性肝炎-肝细胞癌（NASH-HCC）动物模型在实验研究中具有更高的实用价值？]
Zhonghua Gan Zang Bing Za Zhi. 2016 Mar 20;24(3):230-3. doi: 10.3760/cma.j.issn.1007-3418.2016.03.015.
6
Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms.非酒精性脂肪性肝炎（NASH）背景下的肝细胞癌：发病机制的最新进展。
Horm Mol Biol Clin Investig. 2020 Feb 29;41(1):/j/hmbci.2020.41.issue-1/hmbci-2019-0044/hmbci-2019-0044.xml. doi: 10.1515/hmbci-2019-0044.
7
Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View.脂肪性肝病与肝细胞癌：病理医师的视角。
Adv Exp Med Biol. 2018;1032:55-69. doi: 10.1007/978-3-319-98788-0_4.
8
Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?非酒精性脂肪性肝炎相关肝细胞癌：一种日益流行的疾病？
Dig Dis. 2015 Sep;33(5):642-7. doi: 10.1159/000438473. Epub 2015 Sep 23.
9
Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.肝细胞癌与非酒精性脂肪性肝炎：现状
World J Gastroenterol. 2016 Feb 28;22(8):2494-502. doi: 10.3748/wjg.v22.i8.2494.
10
Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).FAT10、FOXO1 和 ADRA2A 在酒精性脂肪性肝炎（ASH）与非酒精性脂肪性肝炎（NASH）患者肝细胞癌发生中的不同作用。
Exp Mol Pathol. 2018 Aug;105(1):144-149. doi: 10.1016/j.yexmp.2018.07.005. Epub 2018 Jul 17.
引用本文的文献
1
Hypoxia-Inducible Factor-2α Promotes Liver Fibrosis by Inducing Hepatocellular Death.缺氧诱导因子-2α通过诱导肝细胞死亡促进肝纤维化。
Int J Mol Sci. 2024 Dec 6;25(23):13114. doi: 10.3390/ijms252313114.
2
Hypoxia-inducible factor-2α promotes fibrosis in non-alcoholic fatty liver disease by enhancing glutamine catabolism and inhibiting yes-associated protein phosphorylation in hepatic stellate cells.缺氧诱导因子-2α 通过增强肝星状细胞中的谷氨酰胺分解代谢和抑制 yes 相关蛋白磷酸化来促进非酒精性脂肪性肝病中的纤维化。
Front Endocrinol (Lausanne). 2024 Feb 28;15:1344971. doi: 10.3389/fendo.2024.1344971. eCollection 2024.
3
The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway.非酒精性脂肪性肝病中的STING：炎症-致癌途径中的潜在治疗靶点
Pharmaceuticals (Basel). 2022 Oct 9;15(10):1241. doi: 10.3390/ph15101241.
本文引用的文献
1
Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation.肝细胞特异性敲除 HIF2α 通过降低癌细胞增殖预防 NASH 相关肝癌发生。
Cell Mol Gastroenterol Hepatol. 2022;13(2):459-482. doi: 10.1016/j.jcmgh.2021.10.002. Epub 2021 Oct 14.
2
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.非酒精性脂肪性肝病相关肝细胞癌：现有和新兴治疗选择的安全性和疗效。
J Hepatol. 2022 Feb;76(2):446-457. doi: 10.1016/j.jhep.2021.09.007. Epub 2021 Sep 20.
3
What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?非酒精性脂肪性肝炎患者的未来如何：2021 年及以后的诊断策略和治疗选择？
Hepatol Commun. 2021 Nov;5(11):1810-1823. doi: 10.1002/hep4.1814. Epub 2021 Sep 9.
4
Nonalcoholic steatohepatitis: global impact and clinical consequences.非酒精性脂肪性肝炎：全球影响及临床后果
Endocr Connect. 2021 Oct 7;10(10):R240-R247. doi: 10.1530/EC-21-0048.
5
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.非酒精性脂肪性肝炎患者肝细胞癌的分子特征。
J Hepatol. 2021 Oct;75(4):865-878. doi: 10.1016/j.jhep.2021.04.049. Epub 2021 May 13.
6
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.NASH 限制了免疫治疗治疗 HCC 的肿瘤监测。
Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24.
7
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016-2020).缺氧诱导因子 (HIF) 抑制剂：专利调查（2016-2020 年）。
Expert Opin Ther Pat. 2021 May;31(5):387-397. doi: 10.1080/13543776.2021.1874345. Epub 2021 Jan 29.
8
Regulation of cancer cell metabolism: oncogenic MYC in the driver's seat.调控癌细胞代谢：致癌基因 MYC 居功至伟。
Signal Transduct Target Ther. 2020 Jul 10;5(1):124. doi: 10.1038/s41392-020-00235-2.
9
HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway.缺氧介导的HIF-2α上调通过PI3K-AKT-mTOR途径激活脂质合成，促进非酒精性脂肪性肝病-肝癌进展。
Aging (Albany NY). 2019 Dec 4;11(23):10839-10860. doi: 10.18632/aging.102488.
10
From NASH to HCC: current concepts and future challenges.从 NASH 到 HCC：当前概念和未来挑战。
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. doi: 10.1038/s41575-019-0145-7.
Zotero 插件